Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401.

    Article  CAS  Google Scholar 

  2. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 2006; 103: 3153–3158.

    Article  CAS  Google Scholar 

  3. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309.

    Article  CAS  Google Scholar 

  4. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127–3132.

    Article  CAS  Google Scholar 

  5. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006; 107: 4334–4337.

    Article  CAS  Google Scholar 

  6. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002; 99: 111–120.

    Article  CAS  Google Scholar 

  7. Wang X, Hochhaus A, Kantarjian HM, Agrawal S, Roy A, Pfister M et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol 2008; 26 (Suppl): 3590.

    Article  Google Scholar 

  8. Xing L, Venegas AM, Chen A, Garrett-Beal L, Boyce BF, Varmus HE et al. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 2001; 15: 241–253.

    Article  CAS  Google Scholar 

  9. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P . Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 1993; 90: 4485–4489.

    Article  CAS  Google Scholar 

  10. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR . Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992; 90: 1622–1627.

    Article  CAS  Google Scholar 

  11. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111: 2538–2547.

    Article  CAS  Google Scholar 

  12. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006–2013.

    Article  CAS  Google Scholar 

  13. Grey A, O'Sullivan S, Reid IR, Browett P . Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006; 355: 2494–2495.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We wish to thank Lee Anne Griffiths, Francis Lee and Richard Smykla from Bristol-Myers Squibb for the provision of dasatinib drug and helpful discussions.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A C W Zannettino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vandyke, K., Dewar, A., Farrugia, A. et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 23, 994–997 (2009). https://doi.org/10.1038/leu.2008.356

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.356

This article is cited by

Search

Quick links